CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Roche Holding Global Data Supports Elecsys Ptau217 And Ptau181 Blood Tests For Accessible Alzheimer's Diagnosis

By Reuters News

Nov 10 (Reuters) - Roche Holding AG ROPC.S:

  • ROCHE PRESENTS NEW DATA ACROSS PHARMACEUTICALS AND DIAGNOSTICS FROM ITS GROWING ALZHEIMER’S DISEASE PORTFOLIO AT CTAD 2026

  • UPDATED PHASE IB/IIA BRAINSHUTTLE AD DATA SHOWS RAPID AMYLOID REMOVAL WITH TRONTINEMAB

  • PHASE III PREVENTRON STUDY FOR TRONTINEMAB IN PRECLINICAL ALZHEIMER'S DISEASE COMMENCES ENROLMENT

  • GLOBAL DATA SUPPORTS ELECSYS PTAU217 AND PTAU181 BLOOD TESTS FOR ACCESSIBLE ALZHEIMER'S DIAGNOSIS

  • PHASE II TARBELA-AD STUDY INITIATED FOR RG6434 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE

  • TO PRESENT NEW DATA AT 19TH CTAD CONGRESS IN BOSTON NOVEMBER 16–19, 2026


Further company coverage: ROPC.S

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.